ACADIA Pharmaceuticals (ACAD) : 5 brokerage houses believe that ACADIA Pharmaceuticals (ACAD) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on ACADIA Pharmaceuticals (ACAD). Zacks Investment Research suggests a Sell with a rank of 4.The median of all the 6 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.33.
ACADIA Pharmaceuticals (ACAD) : The most positive equity analysts on ACADIA Pharmaceuticals (ACAD) expects the shares to touch $60, whereas, the least positive believes that the stock will trade at $40 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $49.13 with an expected fluctuation of $6.94 from the mean.
For the current week, the company shares have a recommendation consensus of Buy.
ACADIA Pharmaceuticals (NASDAQ:ACAD): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $36.44 and $36.00 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $37.38. The buying momentum continued till the end and the stock did not give up its gains. It closed at $37.17, notching a gain of 1.59% for the day. The total traded volume was 1,401,809 . The stock had closed at $36.59 on the previous day.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.